March 22, 2017
Novartis’s acute heart failure drug disappoints at phase III study
Novartis’s acute heart failure (AHF) drug study did not meet its primary endpoint of reduction in cardiovascular death through Day 180 or reduced worsening heart failure through Day five when added to standard therapy